Skip to content

Trail to check the usefulness of local anaesthesia injection given in between muscles of the back to relieve pain in patients suffering from shoulder pain

Role of Erector Spinae Plane block in the management of Shoulder Pain

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/049442
Enrollment
53
Registered
2023-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Erector Spinae Block: Ultrasound guided Erector spinae block with 20 mL of 0.25% bupivacaine and 40 mg of methyl-prednisolone acetate given . NPRS and SPADI are noted every month for 3m

Sponsors

Dr Pradhan Monnaiah K
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age > 18years 2.All patients with a complaint of shoulder pain of any etiology, > 3 months, 3.Patients with previous lack of response to medication and subdeltoid or intra-articular injections, 4.Numeric Pain Rating Scale(NPRS) score of >5 even after conservative management. 5.Normal activity hampered by the restricted active range of motion of the shoulder joint

Exclusion criteria

Exclusion criteria: 1.Patients indicated for surgical intervention. 2.Patient refusal. 3.Patients with pain due to other diseases, such as malignancy, cervical radicular pain, stroke, or uncontrolled diabetes 4.Patients with any coagulopathies, 5.Patients with a skin infection over the shoulder area/ back, 6.Patients with an allergy to local anesthetics, 7.Patients with uncontrolled hypertension. 8.Patients with any shoulder injury during study period.

Design outcomes

Primary

MeasureTime frame
To assess the Pain relief and improvement in quality of life after erector spinae plane injection in shoulder pain casesTimepoint: Assessment to be done before the injection and monthly after the injection for 3 months

Secondary

MeasureTime frame
Evaluate complication and side effects.Timepoint: Assessment before the injection and monthly after the injection for 3 months

Countries

India

Contacts

Public ContactPradhan Monnaiah K

DY Patil Medical College

pradhanmonnaiahk@gmail.com9964837737

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026